Text Size

Egg Oral Immunotherapy (Egg OIT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
University of Arkansas
Information provided by (Responsible Party):
Wesley Burks, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00597558
First received: January 6, 2008
Last updated: September 28, 2012
Last verified: September 2012
History of Changes
  Purpose

The purpose of this study is to determine if children with egg allergy can be desensitized to egg protein and if this desensitization can help them outgrow their egg allergy at an earlier time than normal. Our hypothesis is that children with egg allergy can be orally desensitized to egg protein and that this desensitization will help them outgrow their egg allergy at an earlier time than normal.


Condition Intervention
Food Hypersensitivity
 Drug: Egg white protein

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Egg Allergy in Children Through Oral Desensitization

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Subjects on egg OIT will have a negative double-blind, placebo-controlled food challenge (DBPCFC) to egg when the IgE is < 2 kU/l. [ Time Frame: End of the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Subjects on OIT will have a decrease in serum CAP-FEIA to egg over the course of the study. [ Time Frame: End of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: February 2003
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Egg white protein
Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
 Drug: Egg white protein
Egg white protein powder

Detailed Description:

Egg allergy in children under 5 years of age is extremely common. Egg, along with milk and peanuts, cause 80% of the food allergy reactions in children in the United States. Children have allergic reactions to egg ranging from mild urticaria to systemic anaphylaxis. The current therapy for children with egg allergy is to place the child on an egg-free diet until the allergy is outgrown. Because egg protein is a part of a significant number of processed foods it is difficult to totally avoid all egg proteins. Accidental ingestions leading to reactions to egg can occur with a bite of a cookie (~70 mg of egg protein) or a bite of a cake (~55 mg of egg protein). Children typically do not outgrow their egg allergy for several years. Therefore it would be helpful if a specific form of therapy would make children outgrow their allergic reactions to egg sooner. Egg protein is given to children in this study in small increasing amounts to desensitize them to the egg protein with the goal of helping them to outgrow their allergy.

  Eligibility

Ages Eligible for Study:   1 Year to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Between 1 to 16 years of age
  • Diagnosed egg allergy by CAP FEIA of 7 kU/l or greater (2 kU/l or greater if 2 years old or less) or have had a positive allergic reaction to egg within 6 months.
  • Having eaten egg in his/her diet prior to diagnosis
  • A family that will be able to be compliant with all study visits

Exclusion Criteria:

  • History of anaphylaxis to egg
  • Medical history that would prevent an OFC or DBPCFC to egg
  • Unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00597558

Locations
United States, Arkansas
University of Arkansas
Little Rock, Arkansas, United States, 72202
Sponsors and Collaborators
University of North Carolina, Chapel Hill
University of Arkansas
Investigators
Principal Investigator: Wesley Burks, MD University of North Carolina, Chapel Hill
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Wesley Burks, MD, Chairman, Department of Pediatrics, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT00597558     History of Changes
Other Study ID Numbers: 5111, 5111
Study First Received: January 6, 2008
Last Updated: September 28, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of North Carolina, Chapel Hill:
Egg allergy

Additional relevant MeSH terms:
Food Hypersensitivity
Hypersensitivity
Egg Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

ClinicalTrials.gov processed this record on May 21, 2013